LRRK2 (G2019S)
Sign in to save this workspaceLRRK2 · Variant type: point · HGVS: p.G2019S
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 99.7% | 0.3% | 82.96 |
| 2 | Gilteritinib | 98.6% | 1.4% | 88.97 |
| 3 | Ceritinib | 97.6% | 2.4% | 95.44 |
| 4 | Sunitinib | 96.7% | 3.3% | 91.73 |
| 5 | Axitinib | 95.8% | 4.2% | 93.23 |
| 6 | Alectinib | 95.6% | 4.4% | 95.49 |
| 7 | Defactinib | 94.9% | 5.1% | 92.68 |
| 8 | Pacritinib | 84.9% | 15.1% | 88.64 |
| 9 | Bosutinib | 84.9% | 15.1% | 87.22 |
| 10 | Ruxolitinib | 82.2% | 17.8% | 98.25 |
| 11 | Repotrectinib | 79.7% | 20.3% | 84.21 |
| 12 | Osimertinib | 78.9% | 21.1% | 97.24 |
| 13 | Abemaciclib | 78.1% | 21.9% | 91.48 |
| 14 | Nintedanib | 77.1% | 22.9% | 90.23 |
| 15 | Baricitinib | 77.0% | 23.0% | 97.99 |
| 16 | Lorlatinib | 71.5% | 28.6% | 97.24 |
| 17 | Ponatinib | 70.9% | 29.1% | 78.23 |
| 18 | Upadacitinib | 69.3% | 30.8% | 97.98 |
| 19 | Selpercatinib | 68.3% | 31.7% | 96.72 |
| 20 | Fostamatinib | 64.1% | 35.9% | 96.74 |
| 21 | Abrocitinib | 61.3% | 38.7% | 99.50 |
| 22 | Canertinib | 60.9% | 39.1% | 96.49 |
| 23 | Fedratinib | 57.2% | 42.8% | 96.21 |
| 24 | Vemurafenib | 55.4% | 44.6% | 96.49 |
| 25 | Erlotinib | 51.3% | 48.7% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 99.7% | 96.6% | +3.1% |
| Gilteritinib | 98.6% | 97.2% | +1.3% |
| Ceritinib | 97.6% | 99.4% | -1.8% |
| Sunitinib | 96.7% | 95.8% | +0.9% |
| Axitinib | 95.8% | 92.3% | +3.5% |
| Alectinib | 95.6% | 94.5% | +1.0% |
| Defactinib | 94.9% | 95.8% | -0.9% |
| Pacritinib | 84.9% | 83.4% | +1.5% |
| Bosutinib | 84.9% | 69.5% | +15.4% |
| Ruxolitinib | 82.2% | 63.0% | +19.2% |
| Repotrectinib | 79.7% | 68.8% | +10.9% |
| Osimertinib | 78.9% | 82.4% | -3.5% |
| Abemaciclib | 78.1% | 79.1% | -1.0% |
| Nintedanib | 77.1% | 67.2% | +9.9% |
| Baricitinib | 77.0% | 62.8% | +14.2% |
| Lorlatinib | 71.5% | — | — |
| Ponatinib | 70.9% | 63.4% | +7.5% |
| Upadacitinib | 69.3% | 73.3% | -4.0% |
| Selpercatinib | 68.3% | — | — |
| Fostamatinib | 64.1% | 69.3% | -5.2% |
| Abrocitinib | 61.3% | 62.1% | -0.8% |
| Canertinib | 60.9% | — | — |
| Fedratinib | 57.2% | — | — |
| Vemurafenib | 55.4% | — | — |
| Erlotinib | 51.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_large_intestine | Large Intestine | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms